Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis
Authors:
- Hideto KamedaHKHideto Kameda
- Hiroe OgawaHOHiroe Ogawa
- Hayato NagasawaHNHayato Nagasawa
- Hirofumi TakeiHTHirofumi Takei
- Ayumi OkuyamaAOAyumi Okuyama
- Takahiko KurasawaTKTakahiko Kurasawa
- Tsuneo KondoTKTsuneo Kondo
- Koji NishimuraKNKoji Nishimura
- Yuichiro ShiraiYSYuichiro Shirai
- Ryota SakaiRSRyota Sakai
- Tatsuya ItoTITatsuya Ito
- 22 April 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 23 (1) , 97-103
Abstract
Objective: We investigated the efficacy of a high-dose intermittent dosing treatment method (weekly mizoribine pulse therapy) conceived in the hope of achieving better efficacy by increasing the peak blood levels of mizoribine in patients with refractory lupus nephritis. Methods: Seventeen patients with lupus nephritis who had been resistant to corticosteroid and immunosuppressant therapy received weekly mizoribine pulse therapy. Mizoribine (350 mg) was administered three times at 12 h intervals over 2 consecutive days (700 mg for day 1 and 350 mg for day 2), followed by a washout period from day 3 to day 7. Results: This therapeutic strategy enabled the peak blood levels of mizoribine to be increased to more than 3 μg/mL in most of the patients. Although SLEDAI, anti-ds-DNA antibody titer, CH-50, and serum albumin level did not significantly improve, urinary protein levels decreased, and it was possible to taper the dose of concomitant steroids. Using our definition of clinical response, 10 of the 17 patients were responders and 4 of them were nonresponders. The average peak serum mizoribine concentration of the responders was as high as 3.5 μg/mL. Elevation of serum liver enzymes was seen in 1 patient, and hyperuricemia occurred in 4 cases, but none of these adverse events were serious. Conclusion: Intermittent administration of mizoribine can increase blood levels and may be effective for refractory lupus nephritis.Keywords
This publication has 20 references indexed in Scilit:
- Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndromePediatric Nephrology, 2011
- Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis TrialAnnals of the Rheumatic Diseases, 2010
- Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practiceLupus, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Successful Treatment of Class V+IV Lupus Nephritis with Multitarget TherapyJournal of the American Society of Nephrology, 2008
- Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patientsClinical Rheumatology, 2007
- Safety, tolerability and pharmacokinetics of higher‐dose mizoribine in healthy male volunteersBritish Journal of Clinical Pharmacology, 2006
- Revival of effective and safe high-dose mizoribine for the kidney transplantationClinical Transplantation, 2006
- Functional Interaction of the Immunosuppressant Mizoribine with the 14-3-3 ProteinBiochemical and Biophysical Research Communications, 2000
- Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.Journal of Clinical Investigation, 1991